HCPCS Level II
Q5158
Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg
Codes near Q5158
These sit next to Q5158 in the CMS Level II file. All Q codes
- Q5153Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg
- Q5154Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
- Q5155Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
- Q5156Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
- Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
- Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
- Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
- Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
- Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 65219-0668-01 | Conexxence | FreseniUS Kabi USA, LLC | 60 |
| 65219-0670-01 | Bomyntra | FreseniUS Kabi USA, LLC | 120 |
| 65219-0672-01 | Bomyntra | FreseniUS Kabi USA, LLC | 120 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.